ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.909,14
-0,25%
S&P 500
5.914,08
-0,95%
Dow Jones
42.611,73
-0,88%
Euro vs US Dollar
1,03829
-0,44%
Bitcoin
91.932,82
-1,70%
Pepperstone
Advertisement
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Silence Therapeutics PLC (SLN)

  7. Silence Therapeutics PLC (SLN) News

SLN

Silence Therapeutics (SLN)

Silence Therapeutics PLC
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:SLN
DatumZeitQuelleÜberschriftSymbolFirma
09/12/202414h12Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SLNSilence Therapeutics PLC
09/12/202413h30Business WireSilence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual MeetingNASDAQ:SLNSilence Therapeutics PLC
26/11/202414h00Business WireSilence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare ConferenceNASDAQ:SLNSilence Therapeutics PLC
18/11/202422h54Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SLNSilence Therapeutics PLC
18/11/202420h30Business WireSilence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual MeetingNASDAQ:SLNSilence Therapeutics PLC
14/11/202419h13Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:SLNSilence Therapeutics PLC
14/11/202415h44Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:SLNSilence Therapeutics PLC
14/11/202415h24Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SLNSilence Therapeutics PLC
14/11/202414h00Business WireSilence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:SLNSilence Therapeutics PLC
13/11/202414h00Business WireSilence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare ConferenceNASDAQ:SLNSilence Therapeutics PLC
27/08/202414h00Business WireSilence Therapeutics to Webcast Presentations at Upcoming September Investor ConferencesNASDAQ:SLNSilence Therapeutics PLC
15/08/202413h30Business WireSilence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:SLNSilence Therapeutics PLC
27/06/202413h30Business WireSilence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera PatientsNASDAQ:SLNSilence Therapeutics PLC
24/06/202414h30Business WireSilence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma CollaborationNASDAQ:SLNSilence Therapeutics PLC
20/06/202413h30Business WireSilence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)NASDAQ:SLNSilence Therapeutics PLC
30/05/202414h30Business WireSilence Therapeutics to Present at Jefferies Global Healthcare ConferenceNASDAQ:SLNSilence Therapeutics PLC
17/05/202423h04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SLNSilence Therapeutics PLC
16/05/202420h21Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SLNSilence Therapeutics PLC
16/05/202414h30Business WireSilence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline ProgressNASDAQ:SLNSilence Therapeutics PLC
14/05/202422h27Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:SLNSilence Therapeutics PLC
08/05/202423h14Edgar (US Regulatory)Form DEL AM - Delaying amendmentNASDAQ:SLNSilence Therapeutics PLC
30/04/202414h30Business WireSilence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor ConferenceNASDAQ:SLNSilence Therapeutics PLC
29/04/202414h30Business WireSilence Therapeutics Announces Retirement of Alistair Gray from Board of DirectorsNASDAQ:SLNSilence Therapeutics PLC
08/04/202417h48Business WireSilence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)NASDAQ:SLNSilence Therapeutics PLC
13/03/202412h05Business WireSilence Therapeutics Reports Full Year 2023 Financial Results and Recent Business HighlightsNASDAQ:SLNSilence Therapeutics PLC
13/03/202412h03IH Market NewsMixed Futures Amidst Quiet Economic Schedule; Oil Prices ClimbNASDAQ:SLNSilence Therapeutics PLC
13/03/202412h00Business WireSilence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)NASDAQ:SLNSilence Therapeutics PLC
28/02/202414h00Business WireSilence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024NASDAQ:SLNSilence Therapeutics PLC
23/02/202414h12Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SLNSilence Therapeutics PLC
23/02/202414h00Business WireSilence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 TrialNASDAQ:SLNSilence Therapeutics PLC
 Showing the most relevant articles for your search:NASDAQ:SLN

Kürzlich von Ihnen besucht

BIT
1NEMX
Nemetschek
LSE
ETP
Eneraqua Technologies
LSE
JAGI
Jpmorgan Asia Growth & I...
BOV
DEBB11
Btg Pactual Teva Debentu...
BIT
XZSP
Xtrackers S&p 500 Esg Uc...
BIT
NSCIT6221914
IBRD
AMEX
CFF
Centrue Financial
NASDAQ
ADBE
Adobe
KUCN
TIOETH
Trade Token
TG
CLA
Akari Therapeutics
BIT
I07913
Intesa Sanpaolo
CSE
CVGR
City View Green
LSE
FF29
Cad. Fin.33
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten